Patents Assigned to Deutsches Krebsforschungszentrum Stiftung des Offentlichen
Rechts
-
Patent number: 11931349Abstract: The present invention relates to a pharmaceutically compatible iron chelator or a prodrug thereof for use in treating and/or preventing cancer in a subject suspected or known to comprise hypoxic cancer cells, and use in treatment and/or prevention of a human papillomavirus (HPV) related lesion. The present invention further relates to a use of an iron chelator or prodrug thereof for inducing senescence in a cancer cell, preferably a hypoxic cancer cell; and to a method for inducing an irreversible proliferation arrest in cancer cells comprising a) contacting said cancer cells with an iron chelator or prodrug thereof and, thereby, b) inducing an irreversible proliferation arrest in said cancer cells.Type: GrantFiled: November 23, 2018Date of Patent: March 19, 2024Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Felix Hoppe-Seyler, Julia A. Braun, Karin Hoppe-Seyler
-
Patent number: 11866495Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: January 29, 2020Date of Patent: January 9, 2024Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Jörg Willuda, Mark Trautwein, Uwe Gritzan, Christoph Freiberg, Frank Dittmer, Dorian Schönfeld, Julian Marius Glück, Jessica Pinkert, Eva-Maria Gutierrez, Sven Golfier, Simon Holton, Philip Beckhove, Yingzi Ge
-
Publication number: 20240000907Abstract: The invention is based on the finding that endoplasmic reticulum (ER) stress signalling is associated with the pathogenesis of liver disorders such fatty liver, cirrhosis and hepatocellular carcinoma (HCC), and others. The invention identifies novel targets for liver disease therapy which are involved in ER stress signalling, and thereby pertains to compounds and compositions for medical uses, screening approaches to identify therapeutics as well as diagnostic approaches for the identification of disorders or the stratification of certain liver disease patient groups. The invention also pertains to the use of immune checkpoint inhibitors in combination with the compounds or compositions and/or in the treatment of endoplasmic reticulum (ER) stress signalling induced liver cancers.Type: ApplicationFiled: November 12, 2021Publication date: January 4, 2024Applicant: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Mathias HEIKENWALDER, Xin LI, Pierluigi RAMADORI, Dirk HALLER
-
Patent number: 11851463Abstract: The present disclosure provides immunogenic compositions, such as vaccines, including DNA vaccines, and uses thereof, e.g., which include an annexin core domain to mediate efficient antigen delivery and antigen presentation in order to induce an antigen-specific immune response and/or to treat or prevent infectious diseases and/or cancer.Type: GrantFiled: January 21, 2021Date of Patent: December 26, 2023Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Fatmire Bujupi, Peter Krammer, Heiko Weyd
-
Publication number: 20230406961Abstract: The present invention provides a novel bispecific anti-CD28 antibody format which is bivalent and comprises two CD28 binding sites, and at least one target binding site. The bispecific anti CD28 antibody of the invention is surprisingly advantageous due to its costimulatory activity which is strictly target cell restricted. The bispecific CD28 antibody of the invention is provided for use in the treatment of diseases either alone or in combination with a further bispecific antibody inducing a CD3/T cell receptor signal.Type: ApplicationFiled: November 3, 2021Publication date: December 21, 2023Applicants: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, Eberhard Karls Universität TübingenInventors: Helmut SALIH, Gundram JUNG, Martin PFLÜGLER, Latifa ZEKRI, Timo MANZ
-
Patent number: 11806361Abstract: The present invention provides novel compounds that target thrombocyte activity or aggregation capacity through cellular components for the treatment of diseases associated with Non-Alcoholic Fatty Liver Disease (NAFLD). The invention provides these compounds for treating non-alcoholic steatohepatitis (NASH), a progressed stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and Hepatocellular Carcinoma (HCC). Further provided are pharmaceutical compositions, comprising the compounds of the invention, and methods for screening new NASH therapeuticals.Type: GrantFiled: March 31, 2021Date of Patent: November 7, 2023Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Mathias Heikenwälder, Lars Zender, Achim Weber
-
Patent number: 11802285Abstract: The present invention relates to a compound selectively binding to a sensory receptor or selectively altering the expression of a sensory receptor for use in a method for treating or preventing a disease associated with a pathologic cellular cytotoxic T cell (CTL) response. Further, the invention relates to means for detecting a sensory receptor for use in a method for diagnosing cellular resistance against CTL response in a patient. The invention further embraces a method for determining the resistance of a cell against a CTL response in vitro and to a method for identifying agents that influence the response of cells to CTLs.Type: GrantFiled: September 6, 2019Date of Patent: October 31, 2023Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Philipp Beckhove, Michael Boutros, Nisit Khandelwal, Marco Breinig
-
Patent number: 11773164Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: January 29, 2020Date of Patent: October 3, 2023Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Jörg Willuda, Mark Trautwein, Uwe Gritzan, Christoph Freiberg, Frank Dittmer, Dorian Schönfeld, Julian Glück, Jessica Pinkert, Eva-Maria Gutierrez, Sven Golfier, Simon Holton, Philip Beckhove, Yingzi Ge
-
Publication number: 20230272014Abstract: The disclosure relates to a composition of nanoparticles as carrier for HPV-derived immunogenic fragments and the use of the composition for medical purposes, in particular for immunoprophylaxis or immunotherapy. The invention also relates to a vaccine containing the composition and/or nanoparticles.Type: ApplicationFiled: May 12, 2021Publication date: August 31, 2023Applicants: Life Science Inkubator Betriebs GmbH & Co. KG, Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Armin KÜBELBECK, Angelika RIEMER, Sebastian KRUSE, Eva FEIDT, Agnieszka GRABOWSKA, Ellen JUNGLAS
-
Publication number: 20230257829Abstract: The invention pertains to a method for the identification of the geographic origin of an individual test subject or of an individual group of test subjects, the method comprising the comparison of a test methylation profile obtained from genomic material of the individual test subject or of the individual group of test subjects with one or more predetermined reference methylation profiles each being specific for a distinct geographic origin.Type: ApplicationFiled: July 23, 2021Publication date: August 17, 2023Applicants: Evonik Operations GmbH, DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Sina TÖNGES, Frank LYKO, Geetha VENKATESH, Ranja ANDRIANTSOA, Fanny GATZMANN, Florian BÖHL, Andreas KAPPEL, Emeka Ignatius IGWE, Frank THIEMANN
-
Patent number: 11718662Abstract: Disclosed is a method of diagnosing multiple sclerosis (MS), wherein a blood sample from a patient is incubated with a DNA-replication associated (REP) protein. The present invention relates to a DNA-replication-associated (Rep) protein for use in the diagnosis of multiple sclerosis (MS), wherein (a) an increased amount of Rep protein or fragments thereof in the sample as compared to an amount in a control sample; or an increased amount of anti-Rep protein antibodies with antigen in a sample from a subject as compared to an amount in a control sample correlates with a diagnosis of MS, wherein the Rep protein is MSBI1 Rep or MSBI2 Rep.Type: GrantFiled: April 5, 2019Date of Patent: August 8, 2023Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Harald Zur Hausen, Ethel-Michele De Villiers-Zur Hausen, Timo Bund, Sebastian Eilebrecht
-
Publication number: 20230165953Abstract: The invention pertains to an immunization scheme for inducing or amplifying an immune response involving Variant Surface Glycoproteins as carriers for antigenic structures against which the immune response is targeted. The invention is based on a specific priming and boosting schedule using the array presented and soluble VSG variants. Surprisingly, the immunization scheme of the invention elicits a strong and long-lasting antibody response in the immunized subject and therefore is applicable in vaccination approaches, immunotherapy and in the production of novel antibodies.Type: ApplicationFiled: April 20, 2021Publication date: June 1, 2023Applicant: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Nina PAPAVASILIOU, Gianna TRILLER, Erec STEBBINS, Joseph VERDI
-
Patent number: 11617624Abstract: Disclosed herein is a system for navigated punction, biopsy or ablation comprising a mobile electromagnetic field generator for generating an electromagnetic navigation field which is connected to an apparatus for medical imaging, a needle-like instrument (16), comprising a sterile distal portion (22) and an optionally non-sterile proximal portion (20), a removable protection device (30) for encapsulating the sterile distal portion (22), a sensor (38) suitable for carrying out measurements allowing for determining the position of the sensor (38) within the navigation field, and a sensor carrier (26). The sensor carrier (26) comprises an elongate carrier body (36) having proximal and distal ends. The sensor (38) is attached to or enclosed by said carrier body (36) close to its distal end.Type: GrantFiled: March 6, 2017Date of Patent: April 4, 2023Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Alfred Franz, Lena Maier-Hein
-
Patent number: 11612646Abstract: The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin.Type: GrantFiled: January 16, 2017Date of Patent: March 28, 2023Assignees: Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts, Eberhard Karls Universität TübingenInventors: Helmut Salih, Fabian Vogt, Gundram Jung, Latifa Zekri-Metref
-
Publication number: 20220281931Abstract: The invention features methods for characterizing a cancer as sensitive or resistant to Bcl6 therapies, as well as compositions and methods for inducing the degradation or polymerization of a polypeptide of interest.Type: ApplicationFiled: May 20, 2022Publication date: September 8, 2022Applicants: Dana-Farber Cancer Institute, Inc., Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Benjamin EBERT, Mikolaj SLABICKI, Eric S. FISCHER, Hojong YOON, Jonas KOEPPEL
-
Publication number: 20220195533Abstract: The present disclosure relates to the generation and uses of an improved set of biomarkers that are aryl hydrocarbon receptor (AHR) target genes, designated as “AHR biomarkers.” The AHR biomarkers described herein allow one to efficiently determine AHR activation groups and sub-groups, in particular for an improved classification of tumors. As used herein, AHR activation groups are called “AHR activation signatures”. The AHR biomarkers comprise markers that are important in diagnosis and therapy, for example for selecting patients for treatment with AHR activation modulating interventions, and monitoring of therapy response.Type: ApplicationFiled: March 28, 2020Publication date: June 23, 2022Applicant: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTSInventors: Christiane A. OPITZ, Ahmed SADIK, Saskia TRUMP, Soumya R. MOHAPATRA, Sascha SCHÄUBLE, Erik FÄSSLER, Luis F. SOMARRIBAS PATTERSON
-
Patent number: 11238581Abstract: Disclosed are a method for computer-assisted evaluation of biomarkers in a tissue sample as well as a corresponding system and computer program. The method includes the following steps: providing an image of the tissue sample in which cell nuclei of the tissue as well as biomarkers are represented, automatically determining for a plurality of locations or regions within the image a blood vessel probability that represents a probability that the image at the corresponding location or region represents a blood vessel, automatically determining an assumed blood vessel location within the image based on a distribution of blood vessel probability with respect to the locations or regions within the image, automatically selecting biomarkers represented in the image at locations outside the assumed blood vessel location but within a threshold distance from the assumed blood vessel location, and automatically evaluating the selected biomarkers.Type: GrantFiled: September 19, 2018Date of Patent: February 1, 2022Assignees: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, Brandenburgische Technische Universität Cottbus-Senftenberg, GA Generic Assays GmbHInventors: Cläre Von Neubeck, Rico Hiemann, Alexey Elimport
-
Patent number: 11052102Abstract: The present invention provides novel compounds that target thrombocyte activity or aggregation capacity through cellular components for the treatment of diseases associated with Non-Alcoholic Fatty Liver Disease (NAFLD). The invention provides these compounds for treating non-alcoholic steatohepatitis (NASH), a progressed stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and Hepatocellular Carcinoma (HCC). Further provided are pharmaceutical compositions, comprising the compounds of the invention, and methods for screening new NASH therapeuticals.Type: GrantFiled: June 28, 2017Date of Patent: July 6, 2021Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Mathias Heikenwälder, Lars Zender, Achim Weber
-
Patent number: 11053499Abstract: The present invention relates to oligonucleotide inhibitors of the TSC22D4 activity or expression and their uses for the prevention, treatment, and/or regulation of insulin resistance, metabolic syndrome and/or diabetes and/or for improving insulin sensitivity in a mammal.Type: GrantFiled: April 30, 2020Date of Patent: July 6, 2021Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Stephan Herzig, Mauricio Berriel Diaz, Tobias Schafmeier
-
Patent number: 10953099Abstract: The present invention provides a novel class of dithiocarbamate-metal complexes and their uses in medicine. Also provided by the invention are combinations and pharmaceutical compositions, comprising a dithiocarbamate (or thiuram disulphide) such as disulfiram and cyclodextrin, with a source of a heavy metal. Surprisingly, the inventors found a synergistic potentiation of the anti-tumor effect, when a dithiocarbamate/heavy metal mixture was combined with a cyclodextrin. The compounds and combination of the invention are particularly useful in the treatment of tumor diseases, and other disorders. Provided are the compounds, combination, pharmaceutical compositions and kits, as well as methods for the preparation of the combinations of the invention.Type: GrantFiled: October 13, 2017Date of Patent: March 23, 2021Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Eberhard Amtmann, Nikolas Gunkel, Aubry Miller, Michael Morgen